ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Study sponsor: Abivax S.A. · ABVX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-04-14Actual
Enrollment · participants10Actual
Source updated2026-09-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.